Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Rhea-AI Summary

Azitra (NYSE American: AZTR) announced issuance of U.S. Patent No. 12,606,610 B2 on April 21, 2026, titled "Compositions and Methods for Treatment of Netherton Syndrome with LEKTI Expressing Recombinant Microbes."

The patent covers microbes that secrete LEKTI domains and methods to treat skin diseases and provides broad protection for ATR-12, which is in a Phase 1b trial for Netherton syndrome (≈20,000 patients globally).

Positive

• U.S. patent issued (No. 12,606,610 B2) on April 21, 2026
• Patent scope covers LEKTI-expressing microbes and treatment methods for Netherton syndrome
• ATR-12 protected as lead product candidate while in Phase 1b clinical development

Negative

• ATR-12 remains investigational and is limited to clinical-stage data (Phase 1b)
• No commercialization or approval described; clinical advancement and market outcomes remain uncertain

News Market Reaction – AZTR

-0.45%

2 alerts

-0.45% Session close to close

+3.1% Peak Tracked

-12.7% Trough Tracked

$3.99M Market Cap

0.0x Rel. Volume

In the May 6 session, AZTR declined 0.45%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.1% during that session. Argus tracked a trough of -12.7% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds a new U.S. patent, 12,606,610 B2, covering ATR-12 and related LEKTI-expressin...

Analysis

This announcement adds a new U.S. patent, 12,606,610 B2, covering ATR-12 and related LEKTI-expressing microbes for Netherton syndrome, a disease affecting an estimated 20,000 patients globally. It reinforces Azitra’s IP around its Phase 1b lead program and broader precision dermatology platform. In context of recent financing and NYSE American compliance disclosures, investors may watch how this protection supports partnering potential, future clinical milestones, and overall development of the ATR-12 franchise.

Key Figures

Netherton prevalence: 20,000 patients Patent number: 12,606,610 B2 Patent issue date: April 21, 2026 +1 more

4 metrics

Netherton prevalence 20,000 patients Estimated global Netherton syndrome patient population

Patent number 12,606,610 B2 U.S. patent protecting ATR-12 program

Patent issue date April 21, 2026 U.S. patent issuance date for ATR-12-related IP

Trial phase Phase 1b Current ATR-12 trial stage for Netherton syndrome

Historical Context

5 past events · Latest: Apr 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Clinical poster data	Positive	+11.1%	Preclinical ATR-01 data at ASGCT supporting advancement toward first-in-human trial.
Mar 19	Private placement	Positive	+28.8%	Private placement financing of up to $31.4M including warrant-linked proceeds.
Mar 13	Listing compliance	Negative	-7.5%	NYSE American non-compliance notice tied to low stockholders’ equity and going concern.
Mar 05	Corporate governance	Neutral	+2.5%	Cancellation of 2026 special meeting after lack of quorum and proposal withdrawal.
Feb 27	Earnings and pipeline	Negative	-6.1%	Full-year 2025 loss and low cash alongside ATR-12, ATR-04 and ATR-01 pipeline updates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AZTR often shows price moves aligned with news tone, particularly on financing and clinical updates, with occasional divergence on more procedural announcements.

Recent Company History

Over recent months, Azitra has combined clinical progress with significant corporate and listing developments. A poster on ATR-01 at ASGCT on 2026-04-28 and the ATR-12/ATR-04 updates in full-year 2025 results highlighted a growing precision dermatology pipeline. Financing was strengthened via a private placement of up to $31.4M on 2026-03-19, while NYSE American non-compliance notices on 2026-03-13 underscored balance-sheet and listing risks. The new ATR-12 patent further reinforces the IP aspect of this trajectory.

Key Terms

phase 1b, netherton syndrome, s. epidermidis, lympho-epithelial kazal-type-related inhibitor, +2 more

6 terms

phase 1b medical

"ATR-12 is currently the subject of a Phase 1b trial for the treatment..."

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

netherton syndrome medical

"trial for the treatment of Netherton syndrome... chronic and potentially fatal skin disease"

A rare inherited skin and immune disorder that causes fragile, scaly, inflamed skin, frequent infections, and fragile or unusual hair, like a house with faulty waterproofing that lets problems in. For investors, it matters because the small patient population, severe unmet medical need, and predictable biological cause can make treatments eligible for special regulatory incentives, faster development paths, and premium pricing if a safe, effective therapy is approved.

s. epidermidis medical

"ATR-12, an engineered strain of S. epidermidis that expresses a fragment..."

Staphylococcus epidermidis is a common skin bacterium that can cause infections when it gets into the body, especially by forming slimy coatings called biofilms on medical devices like catheters and implants. Investors care because such infections can drive demand for new diagnostics, antibiotics, coatings and device designs, raise clinical trial and regulatory hurdles, and lead to recalls or liability costs—similar to how barnacles on a ship can slow operations and require costly fixes.

lympho-epithelial kazal-type-related inhibitor medical

"domains of the lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein..."

A lympho-epithelial kazal-type-related inhibitor is a naturally occurring protein that acts like a brake on certain enzymes involved in skin and immune function; when it is missing or defective, those enzymes can run unchecked and damage tissues. For investors, it matters because this protein can be a drug target or biomarker for therapies and diagnostics—changes in its activity can drive clinical trial design, regulatory decisions, and the commercial potential of treatments for related diseases.

recombinant microbes medical

"Treatment of Netherton Syndrome with LEKTI Expressing Recombinant Microbes"

Microorganisms that have had their genetic instructions deliberately changed so they produce new substances or behave differently — like reprogramming a tiny factory to make a specific ingredient. Investors watch them because they can underpin new drugs, industrial products or diagnostics, affecting a company’s potential revenue, manufacturing complexity and regulatory risk; success or failure in developing or scaling these microbes often drives valuation.

genetically engineered bacteria medical

"built around the transdermal delivery of genetically engineered bacteria and proteins."

Living bacterial cells whose DNA has been deliberately changed to give them new abilities, such as producing medicines, breaking down materials, or detecting signals. Think of them as tiny factories that have been rewired with new instructions to perform useful tasks. For investors, genetically engineered bacteria matter because they can create novel products, reduce production costs, and carry regulatory and safety risks that affect a company’s value and timelines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Patent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI protein

ATR-12 is currently the subject of a Phase 1b trial for the treatment of Netherton syndrome

BRANFORD, Conn., May 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the issuance of a new U.S. patent protecting ATR-12, the company's lead product candidate. Azitra is advancing ATR-12 in a Phase 1b clinical trial as a treatment for Netherton syndrome, a chronic and potentially fatal skin disease that is estimated to affect approximately 20,000 patients globally.

The U.S. Patent, number 12,606,610 B2, was issued on April 21, 2026, and is titled, "Compositions and Methods for Treatment of Netherton Syndrome with LEKTI Expressing Recombinant Microbes". The patent covers microbes that secrete one or more domains of the lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein and methods of using these microbes to treat skin diseases, including Netherton's Syndrome.

"We are very pleased that the U.S. Patent Office recognized the substantial ingenuity and innovative work behind the creation of ATR-12," said Francisco Salva, Chief Executive Officer of Azitra. "This new patent confers broad protection for the ATR-12 program as we progress this unique treatment for patients living with Netherton syndrome, a severe skin disorder with no approved therapies. Strengthening our intellectual property portfolio is a key strategic value driver for Azitra as we advance a pipeline of innovative precision dermatology therapies built around the transdermal delivery of genetically engineered bacteria and proteins."

About Azitra, Inc.

Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, ATR-04, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. Azitra is also developing its proprietary filaggrin protein and peptide technologies for the consumer, cosmeceutical market. The new initiative is the first amongst others, which aim to leverage Azitra's microbial genetic engineering platform to manufacture innovative proteins and peptides for the cosmetic and research markets. For more information, please visit https://azitrainc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected closing of the private placement, development of the Company's proprietary filaggrin protein and peptide technologies, and statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies.

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: failure to successfully complete our Phase 1b trial for ATR-12 program; delays in the dosing of our first patient in our Phase 1/2 trial for our ATR-04 program; ineffective product candidates; delays in regulatory approval or changes in regulatory framework outside of our control; inaccurate estimation of addressable markets of our product candidates; failure to timely raise additional required funding; emergence of more efficient competitors or more effective competing treatments; involvement in disputes surrounding the use of our intellectual property crucial to our success; inability to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and dependence on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the SEC on February 27, 2026. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact

Norman Staskey
Chief Financial Officer
staskey@azitrainc.com

Investor Relations 
Tiberend Strategic Advisors, Inc.
David Irish
231-632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald 
646-577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-announces-new-us-patent-protecting-atr-12-program-302763513.html

SOURCE Azitra, Inc.

FAQ

What does Azitra's new U.S. patent (12,606,610 B2) protect for ATR-12 (AZTR)?

The patent protects microbes that secrete one or more LEKTI protein domains and related treatment methods. According to Azitra, the patent covers compositions and methods to treat Netherton syndrome and other skin diseases with LEKTI-expressing recombinant microbes.

When was Azitra's patent for ATR-12 issued and what is its title (AZTR)?

U.S. Patent No. 12,606,610 B2 was issued on April 21, 2026. According to Azitra, the patent is titled "Compositions and Methods for Treatment of Netherton Syndrome with LEKTI Expressing Recombinant Microbes."

What is the clinical status of ATR-12 for Netherton syndrome (AZTR)?

ATR-12 is currently being evaluated in a Phase 1b clinical trial. According to Azitra, the program remains clinical-stage as it advances this engineered S. epidermidis candidate for Netherton syndrome treatment.

How many patients are estimated to have Netherton syndrome, which ATR-12 targets (AZTR)?

Netherton syndrome is estimated to affect approximately 20,000 patients globally. According to Azitra, ATR-12 is being developed specifically as a treatment for this chronic and potentially fatal skin disease.

How does Azitra describe the strategic value of the new ATR-12 patent (AZTR)?

Azitra says the patent strengthens its intellectual property portfolio and provides broad protection for the ATR-12 program. According to Azitra, this supports advancement of its precision dermatology pipeline using genetically engineered bacteria and proteins.